Cargando…
Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) has poor prognosis with limited treatment options, with little therapeutic progress made during the past several decades. DNA damage response (DDR) associated therapies, including radiation and inhibitors of DDR, demonstrate potential efficacy against TNBC, espec...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497895/ https://www.ncbi.nlm.nih.gov/pubmed/34631532 http://dx.doi.org/10.3389/fonc.2021.703802 |
_version_ | 1784580060805595136 |
---|---|
author | Clark, Curtis A. Yang, Eddy S. |
author_facet | Clark, Curtis A. Yang, Eddy S. |
author_sort | Clark, Curtis A. |
collection | PubMed |
description | Triple-negative breast cancer (TNBC) has poor prognosis with limited treatment options, with little therapeutic progress made during the past several decades. DNA damage response (DDR) associated therapies, including radiation and inhibitors of DDR, demonstrate potential efficacy against TNBC, especially under the guidance of genomic subtype-directed treatment. The tumor immune microenvironment also contributes greatly to TNBC malignancy and response to conventional and targeted therapies. Immunotherapy represents a developing trend in targeted therapies directed against TNBC and strategies combining immunotherapy and modulators of the DDR pathways are being pursued. There is increasing understanding of the potential interplay between DDR pathways and immune-associated signaling. As such, the question of how we treat TNBC regarding novel immuno-molecular strategies is continually evolving. In this review, we explore the current and upcoming treatment options of TNBC in the context of DNA repair mechanisms and immune-based therapies, with a focus on implications of recent genomic analyses and clinical trial findings. |
format | Online Article Text |
id | pubmed-8497895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84978952021-10-09 Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer Clark, Curtis A. Yang, Eddy S. Front Oncol Oncology Triple-negative breast cancer (TNBC) has poor prognosis with limited treatment options, with little therapeutic progress made during the past several decades. DNA damage response (DDR) associated therapies, including radiation and inhibitors of DDR, demonstrate potential efficacy against TNBC, especially under the guidance of genomic subtype-directed treatment. The tumor immune microenvironment also contributes greatly to TNBC malignancy and response to conventional and targeted therapies. Immunotherapy represents a developing trend in targeted therapies directed against TNBC and strategies combining immunotherapy and modulators of the DDR pathways are being pursued. There is increasing understanding of the potential interplay between DDR pathways and immune-associated signaling. As such, the question of how we treat TNBC regarding novel immuno-molecular strategies is continually evolving. In this review, we explore the current and upcoming treatment options of TNBC in the context of DNA repair mechanisms and immune-based therapies, with a focus on implications of recent genomic analyses and clinical trial findings. Frontiers Media S.A. 2021-09-24 /pmc/articles/PMC8497895/ /pubmed/34631532 http://dx.doi.org/10.3389/fonc.2021.703802 Text en Copyright © 2021 Clark and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Clark, Curtis A. Yang, Eddy S. Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer |
title | Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer |
title_full | Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer |
title_fullStr | Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer |
title_full_unstemmed | Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer |
title_short | Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer |
title_sort | harnessing dna repair defects to augment immune-based therapies in triple-negative breast cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497895/ https://www.ncbi.nlm.nih.gov/pubmed/34631532 http://dx.doi.org/10.3389/fonc.2021.703802 |
work_keys_str_mv | AT clarkcurtisa harnessingdnarepairdefectstoaugmentimmunebasedtherapiesintriplenegativebreastcancer AT yangeddys harnessingdnarepairdefectstoaugmentimmunebasedtherapiesintriplenegativebreastcancer |